niacinamide and Hepatitis C studies

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.

Hepatitis C: INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.

Research Excerpts

Excerpt	Relevance	Reference
"Sorafenib and chemoembolization of the liver (TACE) have both produced increased survival in hepatocellular carcinoma (HCC)."	9.22	Pilot Study of Intrahepatic Artery Chemotherapy in Combination with Sorafenib in Hepatocellular Carcinoma. ( Bhatia, S; Dinh, VY; Feun, L; Martin, P; Narayanan, G; O'Brien, C; Savaraj, N; Yrizarry, J, 2016)
"Sorafenib (SO) was the first systemic agent to demonstrate a significant improvement in overall survival in patients with advanced hepatocellular carcinoma (HCC); international guidelines now recommend SO as a first-line treatment in patients with unresectable HCC who are not eligible for locoregional therapies and maintain preserved liver function."	7.79	Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit. ( D'Angelo, S; De Cristofano, R; Secondulfo, M; Sorrentino, P, 2013)
"Sorafenib is currently the only approved systemic therapy shown to have efficacy in the treatment of advanced hepatocellular carcinoma (HCC)."	7.79	The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma. ( Cabrera, R; Clark, V; Firpi, R; Horne, P; Limaye, AR; Mills, R; Morelli, G; Nelson, DR; Soldevila-Pico, C, 2013)
"This study was conducted to assess the efficacy and safety of sorafenib monotherapy in clinical practice settings for Korean patients with hepatocellular carcinoma (HCC) related primarily to HBV infection."	7.75	Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area. ( Choi, JI; Kim, CM; Park, BJ; Park, JW; Shim, JH, 2009)
"Sorafenib and chemoembolization of the liver (TACE) have both produced increased survival in hepatocellular carcinoma (HCC)."	5.22	Pilot Study of Intrahepatic Artery Chemotherapy in Combination with Sorafenib in Hepatocellular Carcinoma. ( Bhatia, S; Dinh, VY; Feun, L; Martin, P; Narayanan, G; O'Brien, C; Savaraj, N; Yrizarry, J, 2016)
"Transcatheter arterial chemoembolization (TACE) failure or refractoriness is an indication for sorafenib therapy in patients with advanced hepatocellular carcinoma."	3.80	Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the LCSGJ. ( Arizumi, T; Chishina, H; Hagiwara, S; Inoue, T; Kitai, S; Kono, M; Kudo, M; Minami, Y; Nishida, N; Sakurai, T; Takita, M; Ueshima, K; Yada, N, 2014)
"Sorafenib (SO) was the first systemic agent to demonstrate a significant improvement in overall survival in patients with advanced hepatocellular carcinoma (HCC); international guidelines now recommend SO as a first-line treatment in patients with unresectable HCC who are not eligible for locoregional therapies and maintain preserved liver function."	3.79	Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit. ( D'Angelo, S; De Cristofano, R; Secondulfo, M; Sorrentino, P, 2013)
"Sorafenib is currently the only approved systemic therapy shown to have efficacy in the treatment of advanced hepatocellular carcinoma (HCC)."	3.79	The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma. ( Cabrera, R; Clark, V; Firpi, R; Horne, P; Limaye, AR; Mills, R; Morelli, G; Nelson, DR; Soldevila-Pico, C, 2013)
"This study was conducted to assess the efficacy and safety of sorafenib monotherapy in clinical practice settings for Korean patients with hepatocellular carcinoma (HCC) related primarily to HBV infection."	3.75	Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area. ( Choi, JI; Kim, CM; Park, BJ; Park, JW; Shim, JH, 2009)
"It is widely accepted that hepatocellular carcinoma (HCC) has an annual recurrence rate of approximately 15-20% even after potentially curative treatment, with the 5-year recurrence rate reaching 80-90%."	2.47	Adjuvant therapy after curative treatment for hepatocellular carcinoma. ( Kudo, M, 2011)
"Their hematological malignancies were well-controlled at the time of liver resection."	1.46	Liver resection for hepatocellular carcinoma in patients with hematological malignancies. ( Cheng, SB; Huang, CC; Jan, YG; Lin, HC; Lin, YL; P'eng, FK; Shen, CH; Teng, CJ; Wu, CC; Yang, YS, 2017)

Research

Studies (28)

Authors

Clinical Trials (16)

Trial Overview

Trial Outcomes

Overall Survival (OS)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (17.86)	29.6817
2010's	22 (78.57)	24.3611
2020's	1 (3.57)	2.80

Authors	Studies
Biliotti, E	1
Giampaoli, O	1
Sciubba, F	1
Marini, F	1
Tomassini, A	1
Palazzo, D	1
Capuani, G	1
Esvan, R	1
Spaziante, M	1
Taliani, G	1
Miccheli, A	1
Lin, HC	1
Yang, YS	1
Teng, CJ	1
Shen, CH	1
Jan, YG	1
Cheng, SB	1
Wu, CC	1
Lin, YL	1
Huang, CC	1
P'eng, FK	1
D'Angelo, S	1
Secondulfo, M	1
De Cristofano, R	1
Sorrentino, P	1
Kusano, H	1
Ogasawara, S	1
Akiba, J	1
Nakayama, M	1
Ueda, K	1
Yano, H	1
Kulik, L	1
Vouche, M	1
Koppe, S	1
Lewandowski, RJ	1
Mulcahy, MF	1
Ganger, D	1
Habib, A	1
Karp, J	1
Al-Saden, P	1
Lacouture, M	1
Cotliar, J	1
Abecassis, M	1
Baker, T	1
Salem, R	1
Fitzmorris, P	1
Shoreibah, M	1
Anand, BS	1
Singal, AK	1
Arizumi, T	1
Ueshima, K	1
Chishina, H	1
Kono, M	1
Takita, M	1
Kitai, S	1
Inoue, T	1
Yada, N	1
Hagiwara, S	1
Minami, Y	1
Sakurai, T	1
Nishida, N	1
Kudo, M	2
Shao, YY	1
Shau, WY	1
Chan, SY	1
Lu, LC	1
Hsu, CH	1
Cheng, AL	1
Kwon, YC	1
Bose, SK	1
Steele, R	1
Meyer, K	1
Di Bisceglie, AM	1
Ray, RB	1
Ray, R	1
Dinh, VY	1
Bhatia, S	1
Narayanan, G	1
Yrizarry, J	1
Savaraj, N	1
O'Brien, C	1
Martin, P	1
Feun, L	1
Pár, A	1
Pár, G	1
Shim, JH	1
Park, JW	1
Choi, JI	1
Park, BJ	1
Kim, CM	1
Llanos, L	1
Bellot, P	1
Zapater, P	1
Pérez-Mateo, M	1
Such, J	1
Chen, TJ	1
Lai, PC	1
Yang, LC	1
Kuo, TT	1
Hong, HS	1
Mendizabal, M	1
Reddy, KR	1
Lapecorella, M	1
Napolitano, M	1
Tudini, M	1
Bruera, G	1
Lucchesi, A	1
Giordano, AV	1
Mariani, G	1
Ricevuto, E	1
Perboni, G	1
Costa, P	1
Fibbia, GC	1
Morandini, B	1
Scalzini, A	1
Tagliani, A	1
Cengarle, R	1
Aitini, E	1
Bhoori, S	1
Toffanin, S	1
Sposito, C	1
Germini, A	1
Pellegrinelli, A	1
Lampis, A	1
Mazzaferro, V	1
Finn, RS	1
Herden, U	1
Fischer, L	1
Schäfer, H	1
Nashan, B	1
von Baehr, V	1
Sterneck, M	1
Bruix, J	1
Sherman, M	1
Di Benedetto, F	1
Berretta, M	1
De Ruvo, N	1
Tarantino, G	1
D'Amico, G	1
Ballarin, R	1
Iemmolo, RM	1
Gerunda, GE	1
Kim, BK	1
Kim, SU	1
Park, JY	1
Kim, DY	1
Ahn, SH	1
Park, MS	1
Kim, EH	1
Seong, J	1
Lee, DY	1
Han, KH	1
Friedman, SL	1
Dogan, E	1
Yalcin, S	1
Koca, D	1
Olmez, A	1
Cabrera, R	1
Limaye, AR	1
Horne, P	1
Mills, R	1
Soldevila-Pico, C	1
Clark, V	1
Morelli, G	1
Firpi, R	1
Nelson, DR	1
Ji, F	1
Li, Z	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Single-Center Proof of Concept Pilot Study to Evaluate the Safety, Efficacy, and Tolerability of Sorafenib Combined With Therasphere in Subjects With Hepatocellular Carcinoma Awaiting Liver Transplantation.[NCT00846131]	Phase 1	24 participants (Actual)	Interventional	2009-02-28	Completed
Randomized, Open-label and Multi-center Clinical Trial to Evaluate the Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced Hepatocellular Carcinoma[NCT01897610]	Phase 2	40 participants (Actual)	Interventional	2013-12-31	Completed
The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study[NCT01831037]		0 participants (Actual)	Observational	2015-07-31	Withdrawn (stopped due to Unable to obtain funding)
The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction in Patients With Korean Hepatocellular Carcinoma Patients: Multicenter, Prospective Randomized Double-Blind Controlled Study[NCT03212625]	Phase 4	288 participants (Actual)	Interventional	2016-01-28	Completed
Radiofrequency Ablation Combined With Highly-purified CTL vs. Radiofrequency Ablation Alone for Recurrent HCC[NCT02678013]	Phase 3	210 participants (Anticipated)	Interventional	2016-02-29	Active, not recruiting
Prophylactic Minimally-invasive Local Ablation Therapies for the Hepatic Dysplastic Nodules in Patients With Positive Hepatitis B Surface Antigen (HBsAg).[NCT02793791]		30 participants (Anticipated)	Interventional	2016-09-30	Not yet recruiting
The Combination of Pembrolizumab and Lenvatinib as Neoadjuvant Treatment for Hepatocellular Carcinoma Patients: a Single Arm Phase II Study[NCT05389527]	Phase 2	43 participants (Anticipated)	Interventional	2022-09-30	Active, not recruiting
A Real World Study of Regogfinib in the Treatment of Advanced Hepatocellular Carcinoma[NCT05557656]		800 participants (Anticipated)	Observational	2023-01-05	Not yet recruiting
Stereotactic Image-Guided Microwave Ablation for Hepatocellular Carcinoma - Does Computer-assistance Broaden Eligibility and Efficacy of Ablative Treatment?[NCT03630068]		87 participants (Actual)	Observational	2015-01-01	Completed
A New Track Ablation Device for Liver Biopsy: A Feasibility Study[NCT02521129]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2015-09-30	Not yet recruiting
Transarterial Radioembolization Versus Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma[NCT02729506]	Phase 4	150 participants (Anticipated)	Interventional	2016-01-31	Recruiting
A Randomized Controlled Trial of Laparoscopic Hepatectomy and Radiofrequency Ablation in the Treatment of Early Hepatocellular Carcinoma[NCT02243384]		150 participants (Actual)	Interventional	2014-09-01	Completed
Circulating Tumor Cells and Tumor DNA in HCC and NET - Patient-specific Biomarkers for Clinical Decision Support and Tailored Relapse Diagnostics[NCT02973204]		167 participants (Actual)	Observational [Patient Registry]	2016-11-30	Completed
A Prospective, US Multicenter Open Label Study in the Treatment of Hepatocellular Carcinoma (HCC) With a Radiopaque (RO) Bead (LC Bead LUMI™) Loaded With Doxorubicin[NCT03452553]		0 participants (Actual)	Interventional	2018-07-01	Withdrawn (stopped due to CMS disapproval, no alternative for sites/patient, risk of financial burden.)
Effectivity and Safety of Microwave Ablation Combined With Transcatheter Arterial Chemoembolization(TACE) for Huge Unresectable Hepatocellular Carcinoma: a Multicenter Analysis[NCT03277716]		100 participants (Anticipated)	Interventional	2017-12-01	Recruiting
A Phase III Randomized, Double-blind, Placebo-controlled Study of Sorafenib as Adjuvant Treatment for Hepatocellular Carcinoma After Surgical Resection or Local Ablation.[NCT00692770]	Phase 3	1,114 participants (Actual)	Interventional	2008-08-15	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"OS was defined as the time from randomization to date of death due to any cause. OS for subjects alive at the time of analysis was censored at their last date of contact. NA in the reported data indicates values could not be estimated due to censored data." (NCT00692770)
Timeframe: From randomization of the first subject until 4 years later.

Patient Reported Outcomes: Euroqol-5 Dimensions (EQ-5D) - Index Score

Intervention	Days (Median)
Sorafenib (Nexavar, BAY43-9006)	NA
Placebo	NA

The EQ-5D is a generic quality of life preference based on a validated instrument used in cancer and in general population, with 2 parts: Index and Visual Analogue Scale. The EQ-5D Index is a descriptive system of the following health dimensions: mobility, selfcare, usual activities, pain/discomfort, and anxiety/depression. Subjects were asked to choose any one of the 3 response levels for each dimension: no problems, some problems, and severe problems. The 5 health dimensions were summarized into a single score, the EQ-5D Index score which ranged from -0.59 to 1 with higher scores representing better health states (0=death, 1= perfect health, and -0.59=a health state worse than death). A change of at least 0.10 to 0.12 points was considered a minimally important difference using Eastern Cooperative Oncology Group Performance Status as the anchor. The results on the Analysis of covariance of timeadjusted Area under curve for the EQ-5D index score were reported. (NCT00692770)
Timeframe: Cycle (C) Day (D)1, C2D1, C3D1 and subsequent cycles up to C18, end of intervention visit

Patient Reported Outcomes: Euroqol-5 Dimensions (EQ-5D) - Visual Analogue Scale (VAS) Score

Intervention	Unit on a scale (Least Squares Mean)
Sorafenib (Nexavar, BAY43-9006)	0.827
Placebo	0.866

The EQ-5D is a generic quality of life preference based on a validated instrument used in cancer and in general population, with 2 parts: Index and Visual Analogue Scale. The EQ-5D VAS is a measure that represents health status as a single value. It is a 20-centimetre vertical graduated visual analogue scale with scores that ranged from 0 (worst imaginable health state) to 100 (best imaginable health state). The respondent rated his/her current health state by drawing a line from the box marked 'your own health state today' to the appropriate point on the EQ-5D VAS. A 3-digit number (including leading zeros) was read off the scale from the point where the respondent's line crossed the scale, which was the EQ-5D VAS score. A change of at least 7 points on the VAS was considered as minimally important. The results on the ANCOVA analysis of time-adjusted AUC for the EQ-5D VAS score were reported. (NCT00692770)
Timeframe: Cycle (C) Day (D)1, C2D1, C3D1 and subsequent cycles up to C18, end of intervention visit

Patient Reported Outcomes: Functional Assessment of Cancer Therapy (FACT)- General (G) Total Score

Intervention	Unit on a scale (Least Squares Mean)
Sorafenib (Nexavar, BAY43-9006)	77.203
Placebo	80.181

The PWB, FWB, SWB and EWB were summed to form the FACT-G total score. Subjects responded to each item on a 5-point Likert-type scale ranging from 0 (not at all) to 4 (very much). FACT-G scores ranged from 0 to 108 and the higher scores represented a better quality of life. The MID for the FACT-G total score was in the range of 6 to 7. The results on the ANCOVA analysis of time-adjusted AUC for the FACT-G score were reported. (NCT00692770)
Timeframe: Cycle (C) Day (D)1, C2D1, C3D1 and subsequent cycles up to C18, end of intervention visit

Patient Reported Outcomes: Functional Assessment of Cancer Therapy (FACT)- Hepatobiliary Subscale (HEP) Score

Intervention	Unit on a scale (Least Squares Mean)
Sorafenib (Nexavar, BAY43-9006)	80.46
Placebo	82.95

The FACT-HEP is a 45 item, self-administered, multi-dimensional, psychometrically sound questionnaire used extensively in oncology clinical trials. FACT-HEP consisted of five subscales: Physical Well-Being (PWB), Social Well-Being (SWB), Emotional Well-Being (EWB), Functional Well-Being (FWB), and Hepatobiliary Cancer Subscale (HCS). The PWB, FWB, SWB and EWB were summed to form the FACTGeneral (FACT-G) total score. The FACT-G and HCS scores were summed to form the FACT-HEP total score. FACT-HEP scores ranged from 0 to 180 and the higher scores represented a better quality of life. Subjects responded to each item on a 5-point Likert-type scale ranging from 0 (not at all) to 4 (very much). The minimally important difference (MID) for the FACT-Hep total score was in the range of 8 to 9. The results on the ANCOVA analysis of time-adjusted AUC for the FACT-HEP score were reported. (NCT00692770)
Timeframe: Cycle (C) Day (D)1, C2D1, C3D1 and subsequent cycles up to C18, end of intervention visit

Recurrence Free Survival (RFS) by Independent Assessment

Intervention	Unit on a scale (Least Squares Mean)
Sorafenib (Nexavar, BAY43-9006)	138.7
Placebo	143.79

Disease recurrence of HCC (intra or extra hepatic) was defined as the appearance of a new intrahepatic lesions fulfilling the American Association for the Study of Liver Diseases (AASLD) criteria of diagnosis of HCC or a new extra-hepatic lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.0. In addition to investigator assessment, all images were reviewed by an independent panel of radiologists. The calculation of the RFS was based on the independent evaluation of the scans. RFS was defined as the time from randomization to the first documented disease recurrence by independent radiological assessment or death due to any cause whichever occurred first. For subjects who had not recurred or died at the time of analysis, RFS was censored at their last date of evaluable scan before drop-out for any other reason than recurrence or death. (NCT00692770)
Timeframe: From randomization up to 4 years or until disease recurrence whichever came first

The Correlation Between Plasma Biomarker Levels at Baseline With RFS to Determine Prognostic Value of Biomarkers - AFP

Intervention	Days (Median)
Sorafenib (Nexavar, BAY43-9006)	1014
Placebo	1026

"Biomarker was analyzed at baseline [i.e., before treatment] as a dichotomized variable based on median biomarker levels, and dichotomized into high and low groups using an optimal max chi cut-off approach - not per intervention. As such, results were analyzed according to this stratification. Max-chi square methodology was used to search for the optimal cut point for dichotomization of each plasma biomarker and Kaplan-Meier curves were generated using the optimal cut point for each possible association examined. These biomarker analyses were retrospective and exploratory and of signal generating nature only." (NCT00692770)
Timeframe: At Baseline

The Correlation Between Plasma Biomarker Levels at Baseline With RFS to Determine Prognostic Value of Biomarkers - ANG-2

Intervention	Days (Median)
AFP High Expression Group	668
AFP Low Expression Group	1267

The Correlation Between Plasma Biomarker Levels at Baseline With RFS to Determine Prognostic Value of Biomarkers - MET

Intervention	Days (Median)
ANG-2 High Expression Group	588
ANG-2 Low Expression Group	1260

Time to Recurrence (TTR) by Independent Assessment

Intervention	Days (Median)
MET High Expression Group	841
MET Low Expression Group	NA

"TTR was defined as the time from randomization to the first documented disease recurrence by independent radiological assessment. For subjects who had not recurred at the time of analysis, TTR was censored at their last date of evaluable scan before withdrawal for any other reason than recurrence. NA in the reported data indicates values could not be estimated due to censored data." (NCT00692770)
Timeframe: From randomization up to 4 years or until disease recurrence whichever came first

Article	Year
Management of hepatocellular carcinoma. Journal of cancer research and clinical oncology, 2015, Volume: 141, Issue:5 Topics: alpha-Fetoproteins; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Disease Mana	2015
Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: a meta-analysis of randomized clinical trials. Oncology, 2015, Volume: 88, Issue:6 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Hepatitis B;	2015
Bullous pemphigoid in a renal transplant recipient: a case report and review of the literature. American journal of clinical dermatology, 2009, Volume: 10, Issue:3 Topics: Administration, Cutaneous; Anti-Infective Agents; Clobetasol; Dapsone; Doxycycline; Fatal Outcome; G	2009
Current management of hepatocellular carcinoma. The Medical clinics of North America, 2009, Volume: 93, Issue:4 Topics: Algorithms; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Ther	2009
Adjuvant therapy after curative treatment for hepatocellular carcinoma. Oncology, 2011, Volume: 81 Suppl 1 Topics: Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy,	2011

Article	Year
Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma. Journal of hepatology, 2014, Volume: 61, Issue:2 Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Graft Rej	2014
Pilot Study of Intrahepatic Artery Chemotherapy in Combination with Sorafenib in Hepatocellular Carcinoma. Anticancer research, 2016, Volume: 36, Issue:7 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carbo	2016

Article	Year
Urinary metabolomics of HCV patients with severe liver fibrosis before and during the sustained virologic response achieved by direct acting antiviral treatment. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 143 Topics: Aged; Antiviral Agents; Biomarkers; Hepatitis C; Humans; Hydroxybutyrates; Liver Cirrhosis; Male; Me	2021
Liver resection for hepatocellular carcinoma in patients with hematological malignancies. World journal of surgical oncology, 2017, Nov-02, Volume: 15, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers; Carcinoma, Hepatocellul	2017
Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit. Future oncology (London, England), 2013, Volume: 9, Issue:4 Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Dose-Response Relationship, Drug;	2013
Antiproliferative effects of sorafenib and pegylated IFN‑α2b on human liver cancer cells in vitro and in vivo. International journal of oncology, 2013, Volume: 42, Issue:6 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Caspase 3; Cell	2013
Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the LCSGJ. Oncology, 2014, Volume: 87 Suppl 1 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therap	2014
Promotion of Cancer Stem-Like Cell Properties in Hepatitis C Virus-Infected Hepatocytes. Journal of virology, 2015, Volume: 89, Issue:22 Topics: Animals; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cyclic S-Oxides; Dasatinib; Epithelial-Mesenc	2015
[The 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), Milan, Italy, April 23-27, 2008]. Orvosi hetilap, 2008, Jul-13, Volume: 149, Issue:28 Topics: Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Tria	2008
Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area. Journal of cancer research and clinical oncology, 2009, Volume: 135, Issue:4 Topics: Adult; Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatitis B;	2009
Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib. The American journal of gastroenterology, 2009, Volume: 104, Issue:1 Topics: Acute Disease; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemical a	2009
Sorafenib as a feasible therapeutic option in haemophiliacs with hepatocellular carcinoma. Haemophilia : the official journal of the World Federation of Hemophilia, 2010, Volume: 16, Issue:1 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chronic Disease; Factor V	2010
Sorafenib therapy for hepatocellular carcinoma in an HIV-HCV coinfected patient: a case report. The oncologist, 2010, Volume: 15, Issue:2 Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Comorbidity; Hepatitis C	2010
Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle. Journal of hepatology, 2010, Volume: 52, Issue:5 Topics: alpha-Fetoproteins; Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; beta Catenin; Carcin	2010
Drug therapy: sorafenib. Hepatology (Baltimore, Md.), 2010, Volume: 51, Issue:5 Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis C; Humans; Liver Neoplasm	2010
Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient. Transplantation, 2010, Jul-15, Volume: 90, Issue:1 Topics: Acute Disease; Antineoplastic Agents; Benzenesulfonates; Bilirubin; Carcinoma, Hepatocellular; Chemi	2010
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis	2011
Is advanced hepatocellular carcinoma amenable of cure by liver transplantation with sorafenib as a neoadjuvant approach plus m-TOR inhibitors monotherapy? Journal of surgical oncology, 2012, Volume: 105, Issue:1 Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Combined Modality Therap	2012
Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hep	2012
Focus. Journal of hepatology, 2012, Volume: 57, Issue:5 Topics: Animals; Cell Transformation, Neoplastic; Epithelial-Mesenchymal Transition; Hepatic Veno-Occlusive	2012
Clinicopathological characteristics of hepatocellular carcinoma in Turkey. Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alcoholism; alpha-Fetoproteins; Benzenesulfonates; Bioma	2012
The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma. Alimentary pharmacology & therapeutics, 2013, Volume: 37, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; H	2013
Letter: The antiviral activity of sorafenib in patients with hepatitis C-related hepatocellular carcinoma. Alimentary pharmacology & therapeutics, 2013, Volume: 37, Issue:3 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatitis C; Humans; Liver Neoplasms; Male	2013

niacinamide and Hepatitis C